Holen Sie sich die Stockscreener-App
3.12
0.32%
-0.010
Handel nachbörslich:
3.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Trial tests cholesterol drug in kids with inherited high cholesterol - Stock Titan
ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill
Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur - AD HOC NEWS
Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR) - Seeking Alpha
ETFs Investing in Esperion Therapeutics, Inc. Stocks - TradingView
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97 - MSN
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization - Traders Union
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent - AD HOC NEWS
ESPR Stock Surges 44% in a Month: Here's What You Need to Know - sharewise.com
Drugmaker Esperion gives new hires 260,000 stock units to join - Stock Titan
Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - The Manila Times
Esperion Announces Two New Analyses Supporting Bempedoic - GlobeNewswire
New cholesterol data in kids and statin-intolerant adults at EAS 2026 - Stock Titan
Needham Maintains Esperion Therapeutics(ESPR.US) With Hold Rating - Moomoo
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo
TradingKey - TradingKey
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk - The Globe and Mail
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives - Sahm
Esperion Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR - Stock Titan
Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com
Esperion Therapeutics Q1 2026 earnings preview - MSN
United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq
Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
MSN Money - MSN
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH - Sahm
BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com
Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Needham downgrades Esperion Therapeutics (ESPR) - MSN
BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo
Esperion to be acquired by ARCHIMED - The Pharma Letter
PRN_FinancialWrapper - FinancialContent
Esperion Therapeutics Cut to Hold From Buy by Needham - Moomoo
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal
Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo
Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - FinancialContent
ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade
Penny Stocks To Watch TodayMay 2nd - MarketBeat
ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com
A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Esperion Therapeutics, Inc. $ESPR is AIGH Capital Management LLC's 10th Largest Position - MarketBeat
HC Wainwright & Co. downgrades Esperion Therapeutics (ESPR) - MSN
Crude Oil Down 3%; Chevron Posts Mixed Q1 Results - Benzinga
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Piper Sandler Downgrades Esperion Therapeutics(ESPR.US) to Hold Rating, Cuts Target Price to $3.16 - Moomoo
5.02%
5.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):